Academic Journal
Additional findings.
| العنوان: | Additional findings. |
|---|---|
| المؤلفون: | María del Mar Castro, Astrid C. Erber, Byron Arana, Gláucia Cota, Claudia M. Denkinger, Nicole Harrison, Julia Kutyi, Liliana López-Carvajal, Emma Plugge, Julia Walochnik, Piero Olliaro |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Medicine, Molecular Biology, Cancer, Infectious Diseases, Virology, Computational Biology, users &# 8217, significant indirect costs, respondents expressed views, respective patient ’, qualitative study exploring, provides methodological guidance, matched disease experiences, diagnostics &# 8211, three cutaneous leishmaniasis, patients &# 8217, neglected tropical diseases, adverse events caused, neglected diseases, cutaneous leishmaniasis, adverse events, structured interviews, specific context, safety endpoints, recruited using, rarely involved, mother tongue, meaningfully involved, little access, involving patients |
| الوصف: | Background Target Product Profiles (TPPs) are instrumental to help optimise the design and development of therapeutics, vaccines, and diagnostics–these products, in order to achieve the intended impact, should be aligned with users’ preferences and needs. However, patients are rarely involved as key stakeholders in building a TPP. Methodology Thirty-three cutaneous leishmaniasis (CL) patients from Brazil, Colombia, and Austria, infected with New-World Leishmania species, were recruited using a maximum variation approach along geographic, sociodemographic and clinical criteria. Semi-structured interviews were conducted in the respective patient’s mother tongue. Transcripts, translated into English, were analysed using a framework approach. We matched disease experiences, preferences, and expectations of CL patients to a TPP developed by DND i (Drug for Neglected Diseases initiative ) for CL treatment. Principal findings Patients’ preferences regarding treatments ranged from specific efficacy and safety endpoints to direct and significant indirect costs. Respondents expressed views about trade-offs between efficacy and experienced discomfort/adverse events caused by treatment. Reasons for non-compliance, such as adverse events or geographical and availability barriers, were discussed. Considerations related to accessibility and affordability were relevant from the patients’ perspective. Conclusions/Significance NTDs affect disadvantaged populations, often with little access to health systems. Engaging patients in designing adapted therapies could significantly contribute to the suitability of an intervention to a specific context and to compliance, by tailoring the product to the end-users’ needs. This exploratory study identified preferences in a broad international patient spectrum. It provides methodological guidance on how patients can be meaningfully involved as stakeholders in the construction of a TPP of therapeutics for NTDs. CL is used as an exemplar, but the approach can be adapted for other NTDs. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| Relation: | https://figshare.com/articles/journal_contribution/Additional_findings_/25262262 |
| DOI: | 10.1371/journal.pntd.0011975.s003 |
| الاتاحة: | https://doi.org/10.1371/journal.pntd.0011975.s003 https://figshare.com/articles/journal_contribution/Additional_findings_/25262262 |
| Rights: | CC BY 4.0 |
| رقم الانضمام: | edsbas.9AC00A4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1371/journal.pntd.0011975.s003 |
|---|